ICH Q-IWG Integrated Training Programme
|
|
|
- Octavia Hall
- 5 years ago
- Views:
Transcription
1 Implementation of ICH Q8, Q9, Q10 ICH Q-IWG Integrated Training Programme International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
2 Disclaimer The information within this presentation is based on the ICH Q-IWG members expertise and experience, and represents the views of the ICH Q-IWG members for the purposes of a training workshop. slide 2
3 ICH: 20 years process (1) Start in 1990 (Brussels) Objective of ICH: Technical and scientific harmonisation between Japan, Europe and USA. Scope: New chemical entities and biotechnology derived products Sponsors: - Regulators: EU, FDA, MHLW - Industry: EFPIA, JPMA, PhRMA Observers: - EFTA, Health Canada, WHO Steering Committee slide 3
4 ICH: 20 years process (2) 1990: Pharmacopoeial Discussion Group - EP, JP, USP, WHO 1997: Interested Parties: IGPA, WSMI 1999: Global Cooperation Group RHIs: APEC, ASEAN, GCC, PANDRH, GCG DRAs: Australia, Brazil, China, India, Russia, Singapore, South Korea : DoH: Chinese Taipeh 2003: Quality New Paradigm 2006: Biotech Industry 2010: ICH Training: Implementation Q8, Q9, Q10 slide 4
5 Achieved so far (1) Areas - Quality, Safety, Efficacy - Multidisciplinary areas, MedDRA, e-submission,.. Initial ICH Quality topics - Scientific/technical guidelines mostly: Stability, Method Validation, Impurities, Specifications, Q5 series (Biological) - System oriented: GMP for APIs - Structure: Common Technical Document slide 5
6 Quality: A New Paradigm Develop a harmonised pharmaceutical quality system applicable across the lifecycle of the product emphasizing an integrated approach to quality risk management and science (Brussels July 2003) - Q8: Pharmaceutical Development - Q8 (R2): Pharmaceutical Development Revision - Q9: Quality Risk Management - Q10: Pharmaceutical Quality System - Q11: Development and Manufacture of Drug Substances (chemical/biological entities): in progress. slide 6
7 Quality: A New Paradigm Main message Science is no longer isolated; it is living across the lifecycle of the product/process within a Quality Management System slide 7
8 Quality: A New Paradigm The new paradigm emphasize: 1. Quality must be mainly built in and it will not only improve by additional testing and inspection 2. Better utilization of modern science throughout product lifecycle 3. QRM is a key enabler throughout product lifecycle 4. Robust PQS, with appropriate knowledge management, assures quality throughout product life cycle 5. An integrated approach to development, manufacturing and quality for both industry and regulators slide 8
9 Implementation WG on Q8, Q9, Q10 Task of IWG Q8, Q9, Q10: -.due primarily to departure from the traditional approaches to quality guidance, proper implementation of these concepts is provided by bringing clarity, further explanation and removing ambiguities and uncertainties. - Technical issues & related documentation: - Additional implementation issues: influence on existing ICH guidelines; - Communication and training Unique training programme for industry and regulators (assessors and inspectors) in the three regions: - Tallinn June 2-4, Washington October 6-8, Tokyo October 25-27, 2010 slide 9
10 Structure of Tallinn Training Plenary presentations - Lifecycle of a drug product - Development, Assessment, Manufacturing, Inspection Breakout sessions - Design Space - Control Strategy - Pharmaceutical Quality System - Quality Risk Management Conclusions and next steps slide 10
11 Training on Implementation of Q8, Q9, Q10 Training based on a case study. Integrated implementation of Q8, Q9, Q10 and application to drug products and related operations Opportunity for open dialogue between Regulators and Industry. Feedback from the workshops will be used to further facilitate the understanding and implementation of ICH Q8, Q9 and Q10. slide 11
12 Acknowledgement This presentation has been developed by members of the ICH Quality Implementation Working Group (Q-IWG) Jean-Louis Robert (rapporteur) Diana Amador-Toro Robert G. Baum Nicholas Cappuccino David Cockburn Georges France Richard L. Friedman Nigel Hamilton Hirotada Nagai Yukio Hiyama Fusashi Ishikawa Takao Kiyohara Urs Kopp Akira Kusai Yoshihiro Matsuda Motoaki Mitsuki Elaine Morefield Jacques Morénas Masatoshi Morisue Markus-Peter Müller Tamiji Nakanishi Moheb Nasr Kazuhiro Okochi Anthony Ridgway Rachael Roehrig Stephan Rönninger Swroop Sahota Hideki Sasaki Tetsuhito Takarada Shigeki Tamura Krishnan Tirunellai Mats Welin Jean M. Wyvratt A J van Zyl slide 12
QbD Application in Japan: PMDA Perspective
CMC Strategy Forum Japan 2013 Hotel Okura, Tokyo, Japan, December 9 10, 2013 QbD Application in Japan: PMDA Perspective Yasuhiro Kishioka, PhD. Reviewer Office of Cellular and Tissue based Products Pharmaceuticals
ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective
14 th DIA Japan Annual Meeting 2017 November 12-14, 2017 Tokyo Big Sight Ariake ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective Yasuhiro Kishioka, Ph.D. Principal Reviewer Office
Current Status and Challenges of Bilateral/Multilateral Meetings
Current Status and Challenges of Bilateral/Multilateral Meetings Junko Sato, PhD International Liaison Officer PMDA 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views and
Quality by Design and OINDP. Today s Presentation
Quality by Design and OINDP Setting the Stage John C Berridge IPAC-RS September 2008 Today s Presentation QbD definition Setting the stage from an ICH perspective Future Opportunities 2 QbD Definition
CMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D.
CMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D. Senior Scientist (for Quality) Pharmaceuticals and Medical Devices Agency (PMDA) MFDS Nov 11, 2016 1 Agenda Introduction of PMDA ICH Q12 QbD assessment
ICH Q8, 9 & 10 and the Impact on the QP
1 ICH Q8, 9 & 10 and the Impact on the QP Peter H. Gough David Begg Associates phg@david-begg-associates.com 2 A New Approach to Regulation Approach to the regulation of pharmaceuticals is undergoing a
Challenges of Implementation of ICH Q 8
Challenges of Implementation of ICH Q 8 A Regulatory Perspective Dr. Susanne Keitel BioKorea, Seoul, September 2007 Overview of the Presentation ICH Q 8: Background; EU Experience Design Space Associated
EDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE : 20 YEARS OF EXPERIENCE March EDQM, Strasbourg, France ABSTRACTS
EDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE 1992-2012: 20 YEARS OF EXPERIENCE 22-23 March 2012 EDQM, Strasbourg, France ABSTRACTS PLENARY SESSION, 22 March 2012 ABSTRACT 1.3 The Evolution
Inter-Association Task Force
Inter-Association Task Force Presentation to EMA Workshop Prevention of Drug Shortages Based on Quality and Manufacturing Issues 9 th October 2015 1 Topics for Today Background and history of task force
IGDRP Mission, Scope, How it works
IGDRP Mission, Scope, How it works IGDRP-EDQM Workshop Strasbourg, France 13 May 2016 Dr. Craig Simon Associate Director, Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada
EDQM Conference. Quality of Medicines in a Globalised World: Dreams and Reality
EDQM Conference Quality of Medicines in a Globalised World: Dreams and Reality 14-15 October 2010 Prague, Czech Republic 2010 EDQM, Council of Europe, All rights reserved Plenary Session Dr Moheb M. Nasr
Importance of ICH Guidance in Fulfilling Process Validation Requirements
Importance of ICH Guidance in Fulfilling Process Validation Requirements Presented by: Gamal Amer All rights reserved. Do not copy without permission. Principal 1 Premier Compliance Services, Inc. Process
Claus Mortensen, Medicines Inspector. Danish Medicines Agency. Member of the EMEA PAT team
Claus Mortensen, Medicines Inspector Danish Medicines Agency Member of the EMEA PAT team EMEA progress and status what is needed to document scientific understanding in a PAT application EMEA PAT team
Quality by Design, Clinical Relevance & Lifecycle Considerations
Quality by Design, Clinical Relevance & Lifecycle Considerations Robert Iser Acting Director Office of Process & Facilities / OPQ / CDER IFPAC 2016 1 FDA Quality Related Guidance and Initiatives Initiatives
PMDA perspective on Quality by Design for pharmaceutical products
PMDA perspective on Quality by Design for pharmaceutical products Junichi Fukuchi, Ph.D. Office of Cellular and Tissue-based Products Pharmaceuticals and Medical Devices Agency (PMDA) Annual conference
ICH Q10 Pharmaceutical Quality System
Safeguarding public health ICH Q10 Pharmaceutical Quality System An EU Regulator s Perspective Presentation overview Why does Q10 exist and what were the desired outcomes Content of the Q10 step 2 document
Quality Risk Management
Quality Risk Management Iron Chef Edition Keith D. Gibbs kage and sui generis Ninja Project Management My story shapes my perspective Bachelor of Science work in Earth Science with focus on Hydrogeology.
Implementing Quality Systems
Implementing Quality Systems CGMP By The Sea August 29, 2006 Chris Joneckis, Ph.D. Senior Advisor For CMC Issues Center For Biologics Evaluation And Research Add FDA Bar and Presentation Overview Driving
EU, USA and Japan (II) Reports from Regulators on Exchange Assignments
EU, USA and Japan (II) Reports from Regulators on Exchange Assignments Yoshikazu Hayashi MHLW/PMDA Liaison at EMA PMDA 24th Annual EuroMeeting 26-28 March 2012 Copenhagen, Denmark Disclaimer The views
Q8 and Q8 annex An industry Perspective
Workshop on Implementation of ICH Q8/Q9/Q10 and Other Quality Guidelines Beijing December 2008 Q8 and Q8 annex An industry Perspective Brian Withers, Abbott Laboratories, United Kingdom I attend this conference
Workshop Guide. Joint Regulators/Industry QbD Workshop January 2014 London, UK. europe.pda.org/ema2014
EMA together with other EU Health Agencies Joint Regulators/Industry QbD Workshop 28-29 January 2014 London, UK Workshop Guide europe.pda.org/ema2014 ORGANIZED BY PDA EUROPE Letter from the Chairs Dear
Advisory Board. Advisory Board. Advisory Board (1) GMP Manual (Up05) Maas & Peither AG GMP Publishing
(1) Virginia G. Beakes-Read Genentech, USA Ginny works for Genentech, Inc., as the Director, Regulatory Policy Liaison, for the Strategic Operations Office in Washington, D.C. She works on a variety of
MEDICAL TECHNOLOGY REGULATION. Understanding Where We Have Been and Where We Are Going with Harmonization
GLOBAL HARMONIZATION SUMMIT WASHINGTON DC 18 September 2014 MEDICAL TECHNOLOGY REGULATION Understanding Where We Have Been and Where We Are Going with Harmonization Laurent SELLES Senior Coordinator for
EDQM Conference. Quality of Medicines in a Globalised World: Dreams and Reality
EDQM Conference Quality of Medicines in a Globalised World: Dreams and Reality 14-15 October 2010 Prague, Czech Republic 2010 EDQM, Council of Europe, All rights reserved Dr Georges France Ms Suzette Kox
Global GMP Harmonisation A Japanese Perspective
Global GMP Harmonisation A Japanese Perspective Yukio Hiyama, Ph.D. Chief, Third Section, Division of Drugs, National Institute of Health Sciences, The Ministry of Health Labour and Welfare, JAPAN ISPE
CDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals
CDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals Lawrence X. Yu, Ph.D. Director (acting) Office of Pharmaceutical Science Food and Drug Administration IFPAC
The International Pharmacopoeia Overview
The International Pharmacopoeia Overview Prepared by Caroline Mendy Technical Officer - Quality Assurance and Safety: Medicines The International Pharmacopoeia P Content & Scope WHO Expert Committee on
PHARMACEUTICAL QUALITY MANAGEMENT SYSTEM: A REVIEW
PHARMACEUTICAL QUALITY MANAGEMENT SYSTEM: A REVIEW Available online at www.ijdra.com REVIEW ARTICLE Sharma S*, Bodla R.B., Shweta S, Pathak D.P. Delhi Institute of Pharmaceutical Sciences and Research,
Swissmedic, Swiss Agency for Therapeutic Products
PMDA International Forum, 8 February 2014 Swissmedic, Swiss Agency for Therapeutic Products Jürg H. Schnetzer, Executive Director Grüezi. Bonjour. Buongiorno. Allegra. 2 Overview Swissmedic Introduction
Quality by Design. Innovate Design Development Create value. Correct definition of QbD and its relation to product and process development
Innovate Development Create value Quality by Correct definition of QbD and its relation to product and process development Dr John Loveluck 42 Technology Ltd +44 1480 302700 john.loveluck@42technology.com
Requirements in Other Countries PQRI+USP EI Workshop; Rockville, MD, Dr. Helmut Rockstroh
Requirements in Other Countries PQRI+USP EI Workshop; Rockville, MD, 2015 Dr. Helmut Rockstroh Overview Introduction - Scope Pharmacopoeial + HA Positions Examples / Case Studies Discussion 2 Introduction:
PDA 71 Years of Connecting People, Science and Regulation
PDA 71 Years of Connecting People, Science and Regulation 1 I m happy to be here. Bom Dia. Estou feliz por estar aqui. Richard M. Johnson PDA President & CEO since 2009 38 years experience in US and International
Annual report of the Good Manufacturing and Distribution Practice Inspectors Working Group 2017
17 July 2018 EMA/INS/GMP/19273/2018 Committees and Inspections Annual report of the Good Manufacturing and Distribution Practice Inspectors Working 30 Churchill Place Canary Wharf London E14 5EU United
Global Regulatory Update FDA, USP, EP and ICH Standards for Test Method Validation. Jane Weitzel
Global Regulatory Update FDA, USP, EP and ICH Standards for Test Method Validation Jane Weitzel mljweitzel@msn.com Jane Weitzel Biosketch Jane Weitzel has been working in analytical chemistry for over
Gary Condran Associate Director Bureau of Pharmaceutical Sciences, Therapeutic Product Directorate, HPFB, Health Canada
Gary Condran Associate Director Bureau of Pharmaceutical Sciences, Therapeutic Product Directorate, HPFB, Health Canada EDQM International Conference 19-20 September 2017 1 Concept History Mission Objectives
Quality Regulation under Revised Pharmaceutical Affair Law
Quality Regulation under Revised Pharmaceutical Affair Law Yukio Hiyama, Ph.D. Division of Drugs, National Institute of Health Sciences, the Ministry of Health, Labour and Welfare, Japan E mail hiyama@nihs.go.jp
Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA
EUnetHTA European network for Health Technology Assessment Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA University of Tokyo, October 24,
Progressive Licensing and the Modernization of the Canadian Regulatory Framework
Progressive Licensing and the Modernization of the Canadian Regulatory Framework Workshop on Implementation of ICH Quality Guidelines Beijing, China 3-5 December, 2008 Mike Ward Health Canada 1 DISCLAIMER
ICH Q7 - API. Presented by Ashley Isbel 4 July, 2016
ICH Q7 - API Presented by Ashley Isbel 4 July, 2016 ICH Q7 ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (November 2000) Adopted or referenced by: PIC/S in 2007 - Guide
Value Paper. Are you PAT and QbD Ready? Get up to speed
Value Paper Are you PAT and QbD Ready? Get up to speed PAT and Quality-by-Design As PAT and Quality -by-design (QbD) become an integral part of the regulatory framework, automation group ABB argues more
Impact of ICH Q9 and the application of Risk Management
Safeguarding public health Impact of ICH Q9 and the application of Risk Management An inspector s perspective on the impact on inspectional approaches and expectations Ian Thrussell Strategy and Development
OSIsoft. Users Conference 2013
OSIsoft. Users Conference 2013 Pharmaceutical and Life Sciences: Towards a Recipe Driven Company and the Critical Role of the Real Time Infrastructure Continuous Process Verification By: Martin Browning,
KEY HIGHLIGHTS WORKSHOP 2019
KEY HIGHLIGHTS aenvironmental Monitoring afacility Design apractical Case Studies avisual Inspection aclean Room Behaviours aprocess Simulations arecent 483s, warning Letters and EU Observations WORKSHOP
Implementation of ICH Q8 and QbD An FDA Perspective
ISPE, Yokohama, Japan June 9, 2006 Implementation of ICH Q8 and QbD An FDA Perspective Chi-wan Chen, Ph.D. Office of New Drug Quality Assessment Center for Drug Evaluation and Research Food and Drug Administration
STRATEGIES FOR SUCCESSFUL SCALE-UP USING QUALITY BY DESIGN
STRATEGIES FOR SUCCESSFUL SCALE-UP USING QUALITY BY DESIGN CHRISTOPHER J POTTER ISPE ADVISOR AND CMC CONSULTANT 1 AGENDA Background ICH Guidelines Terms and Definitions Supporting Information ISPE publications
Progress in FDA s Drug Product Quality Initiative. Janet Woodcock, M.D. November 13, 2003
Progress in FDA s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003 Impetus for Initiative: Modernization and continuous improvement in pharmaceutical manufacturing sector slow compared
EU GMP Evolution or Revolution Scope and drivers for EU GMP changes. August Gordon Farquharson
EU GMP Evolution or Revolution Scope and drivers for EU GMP changes August 2015 Gordon Farquharson EU & PIC/S Harmonisation at IWG level now Slide 2 PharmOut 2015 EU & PIC/S Harmonisation (1) What does
What s New with MedDRA Version 18.1 and the MSSO
What s New with MedDRA Version 18.1 and the MSSO David W. Richardson, M.D. Medical Officer, MedDRA MSSO 3 & 10 September 2015 MedDRA was developed under the auspices of the International Conference on
Update on Progress Implementing the LSIF Anti- Counterfeit Medicines Action Plan
2013/SOM1/LSIF/009 Agenda item: 17 Update on Progress Implementing the LSIF Anti- Counterfeit Medicines Action Plan Purpose: Information Submitted by: United States Life Sciences and Innovative Forum Planning
International Regulatory Harmonization and Medical Technology Innovation. Some personal thoughts
International Regulatory Harmonization and Medical Technology Innovation Some personal thoughts Tokyo University Tokyo, 13 April 2012 M. Gropp; Medtronic, Inc., Minneapolis, USA 1 Overview Overview of
RCUK international engagement with Japan
RCUK international engagement with Japan Sophie Laurie Head of International Research Councils UK Strategy Unit Research Councils UK UK Government funded R&D Performing research Higher education institutions
Reflection Paper on synergies between regulatory and HTA issues. DG SANTE Unit B4 Medical products: safety, quality, innovation
Reflection Paper on synergies between regulatory and HTA issues DG SANTE Unit B4 Medical products: safety, quality, innovation STAMP meeting, 28 June 2016 Outline Aim of the Reflection Paper Drafting process
Update from RDE IWG. GRPE January From the sponsors: European Union Japan Korea
Informal document GRPE-78-23 78 th GRPE, 8-11 January 2019 Agenda item 3(c) Update from RDE IWG GRPE January 2019 From the sponsors: European Union Japan Korea Background During last GRPE meeting, EU,
Analytical Development Labs
Analytical Development Labs S-Matrix ADL Purdue Technology Center 5225 Exploration Drive Suite S-2357 Indianapolis, IN 46241 USA URL: www.smatrix.com Overview Major Pharmaceutical companies worldwide use
Quality assurance in the supply chain for pharmaceuticals from the WHO perspective
1 Quality assurance in the supply chain for pharmaceuticals from the WHO perspective Dr Sabine Kopp Quality Assurance and Safety: Medicines Medicines Policy and Standards World Health Organization Presentation
THAILAND PIC/S ACCESSION: JOURNEY TOWARDS THE 49 TH PIC/S PARTICIPATING AUTHORITY. Suchart Chongprasert, Ph.D. Food and Drug Administration Thailand
THAILAND PIC/S ACCESSION: JOURNEY TOWARDS THE 49 TH PIC/S PARTICIPATING AUTHORITY 20 Mar 2015 1 Aug 2016 Suchart Chongprasert, Ph.D. Food and Drug Administration Thailand CONTENTS Historical Evolution
FDA s Evolving Approach to Pharmaceutical Quality
FDA s Evolving Approach to Pharmaceutical Quality Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research 10th Annual FDA Inspections Summit Nov.
Breakfast briefing: Ross DeVol Chief Research Officer Milken Institute September 22, 2011 The Phoenix Park Hotel Washington, DC
Breakfast briefing: Ross DeVol Chief Research Officer Milken Institute September 22, 2011 The Phoenix Park Hotel Washington, DC Study overview Part 1: The Global Biomedical Industry: Understanding the
active pharmaceutical ingredients
APICActive Pharmaceutical Ingredients Committee a sector group of Europe s leading API Conference 18 th APIC/CEFIC European Conference on active pharmaceutical ingredients Amsterdam, The Netherlands 4-6
Study overview. The Global Biomedical Industry: Preserving U.S. Leadership
Presentation for: Voluntary Health Leadership Conference February 9, 2012 Rancho Bernardo Inn San Diego, CA Ross DeVol Chief Research Officer Milken Institute Study overview Part 1: Understanding the Factors
WHO Regulatory Systems Strengthening Program
WHO Regulatory Systems Strengthening Program MVP RHT RSS CRS www.who.int Minimal capacity met Eligibility for vaccine PQ WHO listed NRAs WHO NRA 5 step capacity building Development of NRA benchmarking
APIs global business developments
APIs global business developments Dr Gian Mario Baccalini EFCG Board Member, Chairman of EFCG Pharma Business Committee President & CEO, Euticals S.p.A., Italy EFCG Press Conference, 13th October 2015,
Brazilian industry s activities for international convergence. Walker Lahmann Director of External Trade at ABIFINA Executive Director at Eurofarma
Brazilian industry s activities for international convergence Walker Lahmann Director of External Trade at ABIFINA Executive Director at Eurofarma Mission Congregate companies, institutes and association
Enhancing and focusing EU international cooperation in research and innovation: A strategic approach. Policy Research and Innovation
Enhancing and focusing EU international cooperation in research and innovation: A strategic approach A Rapidly Changing Context From a triad to a multipolar world STI increasingly internationally interconnected
The 21st Session of the Asia-Pacific Regional Space Agency Forum (APRSAF): Dawn of a New Decade
The 21st Session of the Asia-Pacific Regional Space Agency Forum (APRSAF): Dawn of a New Decade 52 nd Session of Scientific and Technical Subcommittee Kazuhiro MIYAZAKI Office for Space Utilization Promotion,
Overview on Medicines Regulation: regulatory cooperation and harmonization in focus
Overview on Medicines Regulation: regulatory cooperation and harmonization in focus Dr Samvel Azatyan Manager, Medicines Regulatory Support Programme Quality Assurance and Safety: Medicines Essential Medicines
The Process Analytical Technology Initiative: PAT and the Pharmacopeias
The Process Analytical Technology Initiative: PAT and the Pharmacopeias Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science CDER, FDA EDQM Spring Conference, Cannes, 3-43 4 May 2004
the SPD company Dr Clive Simon, Principal, The SPD Company.
the SPD company With decades of local and international experience at the coalface, The SPD Company s specialists have built a solid repertoire of in-depth technical knowledge within the highly-regulated
Key Features of Patent and Utility Models Protection
Key Features of Patent and Utility Models Protection Regional Seminar on the Legislative, Economic and Policy Aspects of the Utility Models Protection System, Kuala Lumpur September 3 and 4, 2012 Standard
Office of Pharmaceutical Quality: Why, What, and How?
Office of Pharmaceutical Quality: Why, What, and How? Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research NIPTE Annual Scientific Conference
International Research Collaboration. - Why do it?
Madrid, 25 May 2011 International Research Collaboration - Why do it? Collaboration is increasing 1996 From: Knowledge, Networks and nations; Royal Society 2011 Collaboration is increasing 2008 China has
Connecting People, Science and Regulation
Connecting People, Science and Regulation Bethesda Towers 4350 East West Highway Suite 600 Bethesda, MD 20814 USA Tel: +1 (301) 656-5900 Fax: +1 (301) 986-0296 www.pda.org PDA Europe ggmbh Am Borsigturm
Gordon Johnston Vice President of Regulatory Sciences, Generic Pharmaceutical Association Suzette Kox
Gordon Johnston Vice President of Regulatory Sciences, Generic Pharmaceutical Association Gordon Johnston is Vice President of Regulatory Sciences at the Generic Pharmaceutical Association. In this role,
VICH OUTREACH FORUM 1 st meeting June 26 27, 2012 Brussels - Europe SUMMARY REPORT
VICH/12/044 30 September 2012 FINAL VICH OUTREACH FORUM 1 st meeting June 26 27, 2012 Brussels - Europe SUMMARY REPORT Session 1: Opening of the meeting and chairperson s introduction The meeting was chaired
Access to Research Infrastructures under Horizon 2020 and beyond
Access to Research Infrastructures under Horizon 2020 and beyond JEAN MOULIN A presentation based on slides provided by: the European Commission DG Research & Innovation Unit B4 Research Infrastructures
Nanomaterials: Applications, Implications and Safety Management in the SAICM Context Rob Visser
Nanomaterials: Applications, Implications and Safety Management in the SAICM Context Rob Visser The Regulatory Challenge of Nanotechnology 20 January 2012 Bern, Switzerland 1 SAICM context: ICCM 2 considered
IPEG Convenor Report to CTI
2014/SOM2/CTI/032 Agenda Item: 11.1 IPEG Convenor Report to CTI Purpose: Information Submitted by: IPEG Chair Second Committee on Trade and Investment Meeting Qingdao, China 10-11 May 2014 OAA ISSUE AREA:
SBI/SBSTA: Parties move forward on economic diversification and just transition work
122 SBI/SBSTA: Parties move forward on economic diversification and just transition work Kuala Lumpur, 6 June (Hilary Chiew) Parties to the UNFCCC at the recently concluded climate talks in Bonn agreed
European Commission Health and Consumers Directorate General, Brussels
PDA EUROPE Adalbertstr, 9 16548 Glienicke/Berlin Germany Tel: +49 33056 2377-0 or -10 Fax: +49 33056 2377-77 or -15 www.pda.org OFFICERS Chair Harold Baseman ValSource Chair-Elect Martin VanTrieste Amgen
Chemicals: Future Trends in Production and Use. Implications for Chemicals Management
Chemicals: Future Trends in Production and Use. Implications for Chemicals Management Michael Gribble, ICCA UNEP, DTIE, Chemicals Branch Learning Center, CSD-19 May 3, 2011 HISTORY: 10 SHORT YEARS AGO
BIOPHARMACEUTICAL SECTOR TRAINING SESSION (DAY ONE) 1 SEPTEMBER 2014
APEC Business Ethics for SMEs Forum: Promoting Ethical Environments in the Medical Device & Biopharmaceutical Sectors Sofitel Nanjing Zhongshan Nanjing, China 1-3 September 2014 BIOPHARMACEUTICAL SECTOR
Claudio Pincus, President, The Quantic Group R. Owen Richards, President, Quantic Regulatory Services Daniel Pincus, Consultant, The Quantic Group
FDA Compliance and Regulatory Symposium Understanding the FDA s Latest cgmp Guidances: Opportunities and Pitfalls Claudio Pincus, President, The Group R. Owen Richards, President, Regulatory Services Daniel
TBT Provisions in RTAs: Do they go beyond the TBT Agreement?
TBT Provisions in RTAs: Do they go beyond the TBT Agreement? Xinyi Li Trade Policies Review Division, WTO Secretariat 12 th ARTNeT Capacity Building Workshop December 2016 1 Motives and Objectives TBT
3 rd meeting of the Board of Funders Brussels, 30 June State of Play. Gustav Kalbe. Head of Unit, DG Connect European Commission
3 rd meeting of the Board of Funders Brussels, 30 June 2016 The new Flagship on 51214 Quantum Technologies State of Play Gustav Kalbe Head of Unit, DG Connect European Commission 2 Quantum Technologies
API hapis High Potency Active Pharmaceutical Ingredients. High Potency Active Pharmaceutical Ingredients. Innovation made. Easy.
API hapis High Potency Active Pharmaceutical Ingredients High Potency Active Pharmaceutical Ingredients Innovation made. Easy. 2 High Potency Active Pharmaceutical Ingredients High potency APIs are our
Towards malaria elimination: ADB-supported work at Myanmar FDA
Towards malaria elimination: ADB-supported work at Myanmar FDA Valerio Reggi 25 January 2018 Disclaimer: The views expressed in this paper/presentation are the views of the author and do not necessarily
Simplification of Lighting and Light- Signalling Regulations
Transmitted by the experts from The International Automotive Lighting and Light Signalling Expert Group (GTB) GRE IWG Simplification of the UN Lighting and Light-Signalling Regulations (SLR) Document:
Mapping Your Success 2013 BSI Healthcare Road Show
Mapping Your Success 2013 BSI Healthcare Road Show Welcome & Outline Objectives for Today Please let me introduce myself.. Gary Slack Global Director BSI Medical Devices Based London 2 Changing Global
ENCePP Work Plan
EMA/231507/2012 ENCePP Secretariat European Network of Centres for Pharmacoepidemiology and Pharmacovigilance European Network of Centres for Pharmacoepidemiology and Pharmacovigilance Adopted by the ENCePP
The ETV pilot programme: State of play, standardisation issues
The ETV pilot programme: State of play, standardisation issues David BAXTER & Jean-Pierre SCHOSGER On behalf of Policy context Innovation Union - turning ideas into jobs, green growth and social progress
Guideline for Technology Transfer (Draft)
Scientific Research Granted by the Ministry of Health, Labor and Welfare in 2003 Research on Current Quality System of Drug Products Research Report Yukio Hiyama, Chief Researcher, Division of Drugs, the
Challenges, benefits, case study
hallenges, benefits, case study Pharmaceutical development phases overview The new paradigm for development: Quality by Design (QbD) hallenges Benefits ase study losure and Q&A»»»»»» D. eriani Meet MINITAB,
Show. Updates March Kuala Lumpur, Malaysia otcasia.org #otcasia #derrickandsoo
Show Updates 20-23 March 2018 Kuala Lumpur, Malaysia 2018.otcasia.org #otcasia #derrickandsoo Conference Highlights 10 15 40+ 300+ 200+ engaging plenaries and panel discussions focused country and special
Overview of Health Technology Assessment (HTA) from Asia Pacific Perspective
Overview of Health Technology Assessment (HTA) from Asia Pacific Perspective Hong Li, PhD., MPH Group Director, Bristol-Myers Squibb Adjunct Associate Professor University of Cincinnati, USA; and DUKE-NUS
Biometrics and Standardization. Presentation to BioSec 2nd Open Workshop, 19th and 20th January, 2005
Biometrics and Standardization Presentation to BioSec 2nd Open Workshop, 19th and 20th January, 2005 COPRAS is an FP6 Specific Support Action Project with clear goals Stimulate interaction & exchange between
How CDER is Encouraging Adoption of Emerging Technologies in Pharmaceutical Industry
How CDER is Encouraging Adoption of Emerging Technologies in Pharmaceutical Industry Moderator: Lawrence Yu Speakers: Thomas O Connor & Sharmista Chatterjee Emerging Technology: A Key Enabler for Modernizing
Into Moving Forward to Automated Driving. In this issue: ITS World Congress in Montreal. CARTRE and ERTRAC Joint Workshop
THE NEWSLETTER OF THE CONNECTED AUTOMATED DRIVING IN EUROPE INITIATIVE ISSUE N 4 FEBRUARY 2018 Into 2018 Moving Forward to Automated Driving In this issue: ITS World Congress in Montreal CARTRE and ERTRAC
peace of mind For from development to commercial supply
For peace of mind from development to commercial supply aesica-pharma.com weshouldtalk@aesica-pharma.com @aesica CorporateBroEng_v2 0814 @ Aesica 2014 Your full service CDMO Our vision: To be the number
Corporate Invention Board
Corporate Invention Board Characterizing the nature and extent of technological globalisation Antoine SCHOEN Univ Paris-Est, LATTS, ESIEE, IFRIS The Output of R&D activities: Harnessing the Power of Patents
ERAC-SFIC 1353/15 AFG/nj 1 DG G 3 C
EUROPEAN UNION EUROPEAN RESEARCH AREA AND INNOVATION COMMITTEE Strategic Forum for International S&T Cooperation Secretariat Brussels, 13 February 2015 (OR. en) ERAC-SFIC 1353/15 NOTE Subject: SFIC Work